Revvity, Inc., announced today the launch of the in-vitro diagnostic EURORealTime™ APOE assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is valuable to assess a patient’s risk for side effects prior to the start of an anti-amyloid (beta) therapy for Alzheimer’s disease.
Merck’s Keytruda receives approval greenlight from EU CHMP –
Keytruda is an anti-programmed death receptor-1 therapy that helps enhance the capability of the body’s immune system. Credit: Merck & Co. The European Medicines Agency’s
October 13, 2023